Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Financial results for semaglutide brands Ozempic, Wegovy, Rybelsus
Semaglutide 2.4 mg (Wegovy, Novo Nordisk), 2021
M.BehrensC.DongW.SuraokarM.OzburnN
This indicates that while higher doses may have some impact on kidney function, this effect is reversible and does not occur at lower, more commonly used doses
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity
